The erythropoietin neuroprotective effect: assessment in CABG surgery (TENPEAKS): a randomized, double-blind, placebo controlled, proof-of-concept clinical trial.

The erythropoietin neuroprotective effect: assessment in CABG surgery (TENPEAKS): a randomized, double-blind, placebo controlled, proof-of-concept clinical trial.

BACKGROUND AND PURPOSE: Neurocognitive dysfunction complicates coronary artery bypass surgery. Erythropoietin may be neuroprotective. We sought to determine whether human recombinant erythropoietin would reduce the incidence of neurocognitive dysfunction after surgery. METHODS: We randomly assigned...

Full description

Bibliographic Details
Main Authors:	Haljan, G, Maitland, A, Buchan, A, Arora, R, King, M, Haigh, J, Culleton, B, Faris, P, Zygun, D
Format:	Journal article
Language:	English
Published:	2009

Similar Items

Erythropoietin: still on the neuroprotection road
by: Nelvys Subirós, et al.
Published: (2012-05-01)

Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor
by: Carolina Castillo Hernández, et al.
Published: (2017-01-01)

Neuroprotective effects of erythropoietin in acute ischemic stroke
by: Bahador Asadi, et al.
Published: (2013-01-01)

Erythropoietin Nanobots: Their Feasibility for the Controlled Release of Erythropoietin and Their Neuroprotective Bioequivalence in Central Nervous System Injury
by: Thi Huong Le, et al.
Published: (2022-03-01)

Double-Blind Proof of Existence for Decentralized Identities
by: Jayamine Alupotha
Published: (2023-01-01)

NEUROPROTECTIVE EFFECTS OF ERYTHROPOIETIN: OPPORTUNITIES, PROSPECTS AND REALITY (REVIEW)
by: I. Kladova, et al.
Published: (2014-09-01)

Neuroprotective effects of erythropoietin on rat retinas subjected to oligemia
by: Litia Alves de Carvalho, et al.
Published: (2018-04-01)

Neuroprotective mechanisms of erythropoietin in a rat stroke model
by: Juenemann Martin, et al.
Published: (2020-05-01)

Erythropoietin; a Novel Neuroprotective Agent for Ocular Disorders
by: Khalil Ghasemi Falavarjani, et al.
Published: (2011-01-01)

Erythropoietin as a possible neuroprotective agent in patients with schizophrenia
by: George E. Barreto
Published: (2015-02-01)

An investigation of levetiracetam in Alzheimer's disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study
by: Sen, A, et al.
Published: (2021)

Relieving acute pain (RAP) study: a proof-of-concept protocol for a randomised, double-blind, placebo-controlled trial
by: Thomas Scalea, et al.
Published: (2019-11-01)

Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)
by: Marvin R. McCreary, et al.
Published: (2022-06-01)

An Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study
by: Arjune Sen, et al.
Published: (2021-07-01)

Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial
by: Arnold LM, et al.
Published: (2020-12-01)

Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson’s Disease
by: Federica Rey, et al.
Published: (2021-01-01)

Second-generation non-hematopoietic erythropoietin-derived peptide for neuroprotection
by: Bongki Cho, et al.
Published: (2022-02-01)

Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study
by: Susan Ball, et al.
Published: (2019-10-01)

A double-blind placebo needle for acupuncture research
by: Takakura Nobuari, et al.
Published: (2007-10-01)

Benefits of Fasting Abbreviation with Carbohydrates and Omega-3 Infusion During CABG: a Double-Blind Controlled Randomized Trial
by: Gibran Roder Feguri, et al.

Evaluation and Comparison of Using Low-Dose Aprotinin and Tranexamic Acid in CABG: a Double Blind Randomized Clinical Trial
by: Jafar Hashemi, et al.
Published: (2012-03-01)

Evaluation and Comparison of Using Low-Dose Aprotinin and Tranexamic Acid in CABG: a Double Blind Randomized Clinical Trial
by: Mohammad Hassan Ghaffari Nejad, et al.
Published: (2012-01-01)

Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
by: Fiona Gaughran, et al.
Published: (2020-01-01)

Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms
by: M. Moransard, et al.
Published: (2017-10-01)

Neuroprotective effect of erythropoietin on anesthesia-induced neurotoxicity through the modulation of autophagy in
by: Bon-Wook Koo, et al.
Published: (2024-06-01)

Case of an octogenarian with an asymptomatic double aortic arch undergoing CABG
by: Ryota Nomura, MD, et al.
Published: (2022-07-01)

Double-blind clonazepam vs placebo in panic disorder treatment
by: ALEXANDRE MARTINS VALENÇA, et al.
Published: (2000-12-01)

Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases
by: Federica Rey, et al.
Published: (2019-08-01)

Erythropoietin administration exerted neuroprotective effects against cardiac ischemia/reperfusion injury
by: Titikorn Chunchai, et al.
Published: (2022-01-01)

Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus
by: Jérémie Nadam, et al.
Published: (2007-02-01)

Efficacy of pentoxifylline for the treatment of bipolar I/II patients with treatment-resistant depression: A proof-of-concept, randomized, double-blind, placebo-controlled trial
by: Tavgah Ahmed Merza Mohammad, et al.
Published: (2024-10-01)

Assessment of the Effect of Rehmannia glutinosa Leaf Extract in Maintaining Skin Health: A Proof-of-Concept, Double-Blind, Randomized, Placebo-Controlled Clinical Trial
by: Srivastava S, et al.
Published: (2024-04-01)

The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders—a double-blind, randomized, placebo-controlled proof-of-concept study
by: Lisa-Marie Brunner, et al.
Published: (2024-04-01)

Echocardiographic Evaluation of the Effects of a Single Bolus of Erythropoietin on Reducing Ischemia-Reperfusion Injuries during Coronary Artery Bypass Graft Surgery; A Randomized, Double-Blind, Placebo-Control Study
by: Shervin Ziabakhsh-Tabary, et al.
Published: (2014-03-01)

A Single 60.000 IU Dose of Erythropoietin Does Not Improve Short-Term Aerobic Exercise Performance in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
by: Thomas Haider, et al.
Published: (2020-09-01)

11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial
by: Nantia Othonos, et al.
Published: (2023-02-01)

Double-Blind, Placebo-Controlled Study of Myotoxicity and Neurotoxicity of Bupivacaine in Rats
by: R. E. Lakhin, et al.
Published: (2019-11-01)

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
by: Federico Cavanna, et al.
Published: (2022-08-01)

The Effect of Aspirin on Schizophrenia; A Double Blind Placebo Controlled Study
by: Hamidreza Jamilian, Gevick Hacoupian
Published: (2017-12-01)

Erythropoietin as a Neuroprotective Drug for Newborn Infants: Ten Years after the First Use
by: Serafina Perrone, et al.
Published: (2022-03-01)